Literature DB >> 27060486

Effects of ceftriaxone on ethanol, nicotine or sucrose intake by alcohol-preferring (P) rats and its association with GLT-1 expression.

Youssef Sari1, Jamie E Toalston2, P S S Rao3, Richard L Bell4.   

Abstract

Increased glutamatergic neurotransmission appears to mediate the reinforcing properties of drugs of abuse, including ethanol (EtOH). We have shown that administration of ceftriaxone (CEF), a β-lactam antibiotic, reduced EtOH intake and increased glutamate transporter 1 (GLT-1) expression in mesocorticolimbic regions of male and female alcohol-preferring (P) rats. In the present study, we tested whether CEF administration would reduce nicotine (NIC) and/or EtOH intake by adult female P rats. P rats were randomly assigned to 4 groups: (a) 5% sucrose (SUC) or 10% SUC [SUC], (b) 5% SUC+0.07mg/ml NIC and 10% SUC+0.14mg/ml NIC [NIC-SUC], 15% EtOH and 30% EtOH [EtOH] and (d) 15% EtOH+0.07mg/ml NIC and 30% EtOH+0.14mg/ml NIC [NIC-EtOH]. After achieving stable intakes (4weeks), the rats were administered 7 consecutive, daily i.p. injections of either saline or 200mg/kg CEF. The effects of CEF on intake were significant but differed across the reinforcers; such that ml/kg/day SUC was reduced by ∼30%, mg/kg/day NIC was reduced by ∼70% in the NIC-SUC group and ∼40% in the EtOH-NIC group, whereas g/kg/day EtOH was reduced by ∼40% in both the EtOH and EtOH-NIC group. The effects of CEF on GLT-1 expression were also studied. We found that CEF significantly increased GLT-1 expression in the prefrontal cortex and the nucleus accumbens of the NIC and NIC-EtOH rats as compared to NIC and NIC-EtOH saline-treated rats. These findings provide further support for GLT-1-associated mechanisms in EtOH and/or NIC abuse. The present results along with previous reports of CEF's efficacy in reducing cocaine self-administration in rats suggest that modulation of GLT-1 expression and/or activity is an important pharmacological target for treating polysubstance abuse and dependence.
Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EAAT2; addiction; alcohol; ceftriaxone; drinking; polysubstance

Mesh:

Substances:

Year:  2016        PMID: 27060486      PMCID: PMC4853280          DOI: 10.1016/j.neuroscience.2016.04.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  60 in total

Review 1.  Homers regulate drug-induced neuroplasticity: implications for addiction.

Authors:  Karen K Szumlinski; Alexis W Ary; Kevin D Lominac
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

2.  Effects of chronic ethanol treatment on the expression of calcium transport carriers and NMDA/glutamate receptor proteins in brain synaptic membranes.

Authors:  X Chen; M L Michaelis; E K Michaelis
Journal:  J Neurochem       Date:  1997-10       Impact factor: 5.372

3.  Ethanol exposure decreases glutamate uptake in the nucleus accumbens.

Authors:  Roberto I Melendez; Megan P Hicks; Stephanie S Cagle; Peter W Kalivas
Journal:  Alcohol Clin Exp Res       Date:  2005-03       Impact factor: 3.455

4.  Ceftriaxone attenuates acute cocaine-evoked dopaminergic neurotransmission in the nucleus accumbens of the rat.

Authors:  J L Barr; B A Rasmussen; C S Tallarida; J L Scholl; G L Forster; E M Unterwald; S M Rawls
Journal:  Br J Pharmacol       Date:  2015-10-22       Impact factor: 8.739

5.  Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species.

Authors:  R R Holson; B Pearce
Journal:  Neurotoxicol Teratol       Date:  1992 May-Jun       Impact factor: 3.763

6.  Ethanol withdrawal seizures and the NMDA receptor complex.

Authors:  K A Grant; P Valverius; M Hudspith; B Tabakoff
Journal:  Eur J Pharmacol       Date:  1990-02-13       Impact factor: 4.432

7.  Glutamate transporter activation enhances nicotine antinociception and attenuates nicotine analgesic tolerance.

Authors:  Joseph A Schroeder; Katrina F Quick; Paige M Landry; Scott M Rawls
Journal:  Neuroreport       Date:  2011-12-21       Impact factor: 1.837

8.  Intravenous nicotine injection induces rapid, experience-dependent sensitization of glutamate release in the ventral tegmental area and nucleus accumbens.

Authors:  Magalie Lenoir; Eugene A Kiyatkin
Journal:  J Neurochem       Date:  2013-10-21       Impact factor: 5.372

9.  Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes.

Authors:  Seok-Geun Lee; Zhao-Zhong Su; Luni Emdad; Pankaj Gupta; Devanand Sarkar; Alejandra Borjabad; David J Volsky; Paul B Fisher
Journal:  J Biol Chem       Date:  2008-03-07       Impact factor: 5.157

10.  An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Daniel E Falk; Hsiao-ye Yi; Susanne Hiller-Sturmhöfel
Journal:  Alcohol Res Health       Date:  2006
View more
  22 in total

1.  Effects of ceftriaxone on conditioned nicotine reward in rats.

Authors:  Helene L Philogene-Khalid; Steven J Simmons; John W Muschamp; Scott M Rawls
Journal:  Behav Pharmacol       Date:  2017-09       Impact factor: 2.293

2.  Effects of chronic inhalation of electronic cigarettes containing nicotine on glial glutamate transporters and α-7 nicotinic acetylcholine receptor in female CD-1 mice.

Authors:  Fawaz Alasmari; Laura E Crotty Alexander; Jessica A Nelson; Isaac T Schiefer; Ellen Breen; Christopher A Drummond; Youssef Sari
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-03-27       Impact factor: 5.067

Review 3.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

Review 4.  Disentangling the Role of Astrocytes in Alcohol Use Disorder.

Authors:  Louise Adermark; M Scott Bowers
Journal:  Alcohol Clin Exp Res       Date:  2016-08-01       Impact factor: 3.455

Review 5.  The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.

Authors:  Edward Pajarillo; Asha Rizor; Jayden Lee; Michael Aschner; Eunsook Lee
Journal:  Neuropharmacology       Date:  2019-03-06       Impact factor: 5.250

Review 6.  Gene and cell therapy on the acquisition and relapse-like binge drinking in a model of alcoholism: translational options.

Authors:  María Elena Quintanilla; Fernando Ezquer; Paola Morales; Mario Rivera-Meza; Eduardo Karahanian; Marcelo Ezquer; Mario Herrera-Marschitz
Journal:  Gene Ther       Date:  2019-02-28       Impact factor: 5.250

7.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 8.  Glial and neuroinflammatory targets for treating substance use disorders.

Authors:  Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

Review 9.  Neuroimmune signaling in alcohol use disorder.

Authors:  Emma K Erickson; Emily K Grantham; Anna S Warden; R A Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-12-24       Impact factor: 3.533

Review 10.  Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis.

Authors:  Ronald Kim; Kati L Healey; Marian T Sepulveda-Orengo; Kathryn J Reissner
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-10-06       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.